GHRP-2 3mg+GHRP-6 3mg+Sermorelin 3 mg=9mg (Blend)
Growth Hormone Releasing Peptide 2
Peptide Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Formula: C45H55N9O6
Molar Mass: 817.9 g/mol
CAS Number: 158861-67-7
price is base on per vial
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
The polypeptide GHRP 2 is a secretogogue that has a molecular formula of C45H55N9O6 and a molecular weight of 817.9. It is comprised of six different amino acids, thus making it a hexipeptide. Its name is an acronym for Growth Hormone Releasing Peptide. It can be sometimes known as GHRP or KP-102.
GHRP – 2 at a Glance
Scientific study that has been based on animal test subjects has determined that GHRP-2’s overall functionality and operational mechanic can be primarily tied to the production of the pituitary gland; the pea-sized gland that is located at the bottom of the hypothalamus at the base of the brain which is chiefly responsible for regulating several of the body’s basic regulatory functions, ranging from growth and metabolism to internal water regulation and pain relief. GHRP 2 has been shown to elevate the functionality of the pituitary gland by promoting the stimulation of secretions from somatropic cells from within the gland.
At the same time, it has been shown to prevent somatostatin; the peptide secretion that regulates the endocrine system and affects neurotransmission and cellular proliferation via interaction with G-coupled receptors. In addition, scientific study based on animal test subjects has determined that the peptide can boost levels of calcium ion influx, which in turn can also stimulate the production of more secretions related to growth.
GHRP – 2 and Ghrelin
Another key component of GHRP 2’s overall operational mechanics can be traced to the peptide’s relationship with the stomach – specifically, its relationship with a self-regulated 28 amino acid enzyme known as ghrelin.
In essence, the secretion of ghrelin serves two purposes:
- It causes the sensation of hunger within animal test subjects
- It balances the secretion of leptin, an enzyme whose expression creates the sensation of feeling full
GHRP-2 has been shown to boost the levels of ghrelin production, thus causing an animal test subject to feel a sense of hunger for a longer, more substantial period of time. This then will elevate the desire that an animal test subject will have in regards to consuming food. In turn, this elevated food intake converts to the boost in fuel that is ultimately a key player in GHRP-2’s ability to boost protein synthesis.
GHRP – 2 and IGF-1
Additional scientific study that has been based on animal test subject has shown that GHRP 2’s functionality enables it to work in conjunction with the liver to produce a greater secretion level of IGF-1. Also known as Insulin-like Growth Factor-1 or Somatomedin C, IGF-1 has been shown to exhibit highly reactive qualities. What this means is, it has been shown to be vital in the growth and repair of muscles and tissues. Because GHRP-2 has been shown to boost levels of IGF-1, it is thought that this ability along with its faculty for increasing protein synthesis can allow an animal test subject to experience a boosted level of muscle size and mass. What’s more, it has also led to the notion that it can promote a more efficient means of tissue repair, which can ultimately translate into a more efficient means of injury recovery.
Other Positive Effects
The proliferation of muscular and skeletal tissue is not the only elevated process that has been associated with GHRP-2. For example, scientific study that has been based on animal test subjects has led to the theory that its ability to increase protein synthesis can lead to a more efficient means of breaking down adipose tissue, also known as body fat. This then has led to the thought that the presence of the peptide can lead to an ability to lose weight more efficiently, despite the fact that GHRP 2’s ability to stimulate ghrelin could lead to an animal test subject increasing its food intake.
Other elevated process that scientific study based on animal test subjects has tied to GHRP-2’s functionality and operational mechanics include a lowering of cholesterol levels, and improved bone density an enhanced defense of the liver, an improved skin elasticity, and an enhanced measure of anti-inflammatory action.
Set Aside for Scientific Research
It should be emphasized that despite the extensive amount of research and study that has been conducted in order to pinpoint the functionality and mechanics of GHRP 2, it is only intended for the sole use of scientific study at this time. All of the research and findings that have been determined and discussed are completely built around the scientific study on animal test subjects. Because of this, any findings or observations that can be tied to GHRP-2’s overall functionality, mechanics, or theoretical benefits should exclusively be contained to a laboratory, a medical research facility, or another strictly controlled environment in this vein.
Growth Hormone Releasing Peptide 6
Peptide Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Molecular Formula: C45H55N9O6 Molar Mass: 817.9 g/mol CAS Number: 158861-67-7
Important Notification: All of our products and services listed in this website are for research or production use only, not for direct human use.
The hexipeptide GHRP – 6 is a secretagogue peptide that has a molecular formula of C46H56N12O6and a molecular weight of 873.014. Its structure is comprised of six amino acids. The name of the peptide itself is an acronym that stands for Growth Hormone Releasing Peptide.
GHRP – 6 and the Pituitary Gland
Scientific study that has been based on animal test subjects has determined that the way in which GHRP 6 has been shown to function chiefly ties into its relationship with the pituitary gland; the tiny, pea-sized gland that is located at the bottom of the hypothalamus at the base of the brain. In essence, this gland is charged with the regulation and control of a host of different processes that are tied to the endocrine system. Some of these processes include metabolism, thyroid gland functionality, temperature regulation, internal water regulation, pain relief, and growth. GHRP – 6’s overall functionality is such that it inhibits the pituitary gland from blocking the production of secretions that directly tie to these regulatory processes. This then allows for the animal test subject to have the ability experience a more efficient means of achieving a level of homeostasis in regards to these regulatory processes.
GHRP – 6 and the Stomach
It has also been determined by scientific study based on animal test subjects that GHRP – 6’s overall functionality can be linked to the production of ghrelin. In essence, ghrelin is an amino acid that is primarily produced by the cells that line the stomach, although it has been noted that it can also be secreted by the epsilon cells that are found in the pancreas. The expression of this particular secretion serves to stimulate the sensation of hunger; this allows it to act as a counterbalance to amino acid leptin, whose secretion stimulates the sensation of feeling full. Studies have indicated that GHRP – 6’s functionality allows for a greater level of ghrelin to be produced. This extra level of production prolongs the amount of which an animal test subject can experience hunger. This in turn enables the test subject to intake a greater amount of food which can then be used as fuel for the pituitary gland’s elevated ability to secrete endocrine system-related expressions.
GHRP – 6 and the Liver
Further scientific study that has been based on animal test subjects has determined that GHRP – 6’s abilities have a connection with the liver; specifically, with a liver-based secretion known as Insulin-like Growth Factor-1, or IGF-1. This secretion has been shown to be highly reactive in nature, meaning that its expression has been tied to the growth and repair of muscle and tissue growth. Studies have indicated that GHRP – 6 has the capacity to influence an elevated production amount of this particular secretion, thus allowing an animal test subject a more efficient rate in achieving homeostasis on a muscular and skeletal tissue level.
GHRP – 6 and the Central Nervous System
It has also been determined through scientific study based on animal test subjects that the presence of GHRP – 6 aids in the activation of intracellular signaling pathways along the central nervous system; these pathways are ones that are used by various secretions that are tied to the pituitary gland. Additionally, it has been shown that it has the ability to promote a greater level of protein expression in terms of overall cellular survival. These functions have led to the determination that it could be a prime ally in the guarding against cell loss and functionality in the aftermath of a hypoxic-ischemic brain injury, such as:
- Angina Pectoris caused by cardiac arrest
- Angina Pectoris caused by respiratory arrest
Various Elevated Processes
Because of the way in which GHRP 6 has been shown to function, scientific study that has been based on animal test subjects has been able to determine that its presence can be responsible for several elevated processes. These processes have been thought to include an increase in muscle growth, a decrease in body fat, an elevation in muscle and tissue repair, an expedited rate of recovery from injury, a boost in bone density, increased immune system efficiency, and a boost in connective tissue and joint strengthening.
Strictly for Controlled Environments
It should be noted that any findings or observations that relate to GHRP – 6 and its overall functionality should exclusively be done within a strictly controlled environment, such as a medical research facility or a laboratory. The reason for this is due to the fact that the peptide and the study its operational is currently just fit for scientific study on animal test subjects. As such, it should be noted that research that has been derived regarding GHRP – 6 is due to scientific tests conducted in a controlled environment only.
Molecular formula: C149H246N44O42S
Molar Mass: 3357.96
CAS number: 86168-78-7
Synonyms: Sermorelin acetate hydrate, GRF 1-29 NH2
Sermorelin Acetate, also known as GRF 1-29, is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH). Sermorelin Acetate was first developed in the 70s, which is thought to be the shortest fully functional fragment of GHRH and has been used as a test for Growth Hormone secretion. It is often used extensively in Anti-aging Therapy along with Testosterone in men. Sermorelin Acetate affects a more primary source of failure in the GH neuroendocrine axis, has more physiological activity, and its use for adult hormone deficiency is not restricted. Compared to human Growth Hormone (h-GH), Sermorelin Acetate is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Also, Sermorelin Acetate and Modified GRF 1-29 contains 29 amino acids whereas h-GH is a larger molecule containing 191 amino acids.
What is Sermorelin?
Sermorelin is a GHRH (growth hormone–releasing hormone) peptide analogue. Its peptide sequence is comprised of 29 amino acids. This sequence is a portion of the endogenous human GHRH, and is currently considered to be the shortest synthetic peptide that possesses the full array of functional GHRH activity. Due to this fact, sermorelin is considered to be a growth hormone secretagogue.
Sermorelin has been used during research to stimulate the secretion of growth hormone from the adenohypophysis (also called the anterior pituitary). The anterior pituitary secretes trophic hormones. Sermorelin has also been used in research stimulation tests to assess for pituitary sufficiency in relation to the secretion of the growth hormone.
Growth hormone–releasing hormone
GHRH is 44 amino-acids polypeptide that stimulates the secretion of growth hormone from the adenohypophysis. It is also called somatocrinin or somatoliberin. It is produced in the cell bodies of periventricular arcuate neurons, and thereafter transported to the neurosecretory terminals of the neurons where they are released. The arcuate neurons do form part of the hypothalamo-hypophyseal portal system. Their release from the neurosecretory terminals occur in a pulsatile fashion and it thus follows that growth hormone (GH) release also occurs in a corresponding pulsatile fashion. GHRH binds to a secretin-type G-protein coupled serpentine receptor called the GHRH-receptor (GHRHR). Binding causes the receptor to activate both the cAMP (cyclic Adenosine Monophosphate)-dependent pathway and the phospholipase C (PLC) pathway. The terminal downstream actions of the cAMP-dependent pathway do upregulate the transcription of both the GH and GHRHR genes thereby providing a positive feedback loop that amplifies the production of GH. The GH produced is thereafter packaged in secretory vesicles. The downstream actions of the PLC pathway results in both Na+-voltage-dependent and Ca2+-dependent fusion of the secretory vesicles with the plasma membrane thereby releasing GH into the bloodstream.
The actions of GH ensure an optimal well-regulated post-natal growth. GH also promotes efficient energy metabolism. Studies have also shown that GHRH directly promotes slow wave NREM (non-rapid eye movement) sleep, and thus GHRH insufficiency causes a reduction in the amount and intensity of slow wave NREM sleep which results in either insomnia or dysomnia (sleep disorders that causes sleep to lose its restorative capacity). Studies have also shown that GHRH inhibits the actions of somatostatin. Somatostatin is a polypeptide hormone that inhibits GH secretion from the adenohypophysis. Both GHRH and somatostatin are produced in the same neuron but they are released in alternation to each other thereby resulting in the pulsatile release of GH from the neuron.
Recent research has also shown that GHRH is also produced outside the hypothalamus by pancreatic cells, gastrointestinal tract epithelial cells and in some neoplastic cells. Clinical studies have also shown that the actions of Sermorelin are similar to the GHRH actions. Thus, Sermorelin has been used to diagnose deficiencies in GH secretions. Also, Sermorelin has been investigated for its therapeutic properties as the studies discussed below show.
The two studies reviewed hereafter have provided adequate and conclusive findings that sermorelin can be used clinically to promote growth and manage GHRH deficiency.
- Sermorelin and growth hormone (GH) deficiency.
In 1999, a study entitled “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency” was authored by Aitabh Prakash and Karen Goa and published in the journal Biodrugs. The aim of this study was to investigate whether sermorelin injection stimulates GH secretion from the adenohypophysis. The subjects of this study included adults and pre-pubertal children (both normal and those suffering from GH deficiency). The subjects were randomly divided into two groups with one group receiving intravenous sermorelin injection and the other group receiving subcutaneous sermorelin injection.
The results obtained from both groups showed that Sermorelin was able to rapidly diagnose GH insufficiency in children affected by GH deficiency (p < 0.05). The p<0.05 is a measure of statistical significance, and the value 0.05 shows that the results are statistically significant. However, the diagnosis could only isolate GH insufficiency caused by GHRH deficiency. The results also revealed that subcutaneous sermorelin injection did cause a significant increase in height in children suffering from idiopathic GH deficiency, and that this acceleration in growth rate could be maintained consistently for 36 months. Likewise, the results also revealed that both Sermorelin administrations were well tolerated with the only observable adverse effects being injection-site pain and transient facial flushing.
In summary, the findings of this study show that sermorelin stimulates GH secretion from the adenohypophysis. Also, intravenous sermorelin can be used to diagnose some cases of GH deficiency, and subcutaneous sermorelin can be used to manage GH insufficiency.
- Sermolelin and growth acceleration in a chronic disease state.
In 1996, Pasqualini et al conducted a study that was published under the title “Growth acceleration in children with chronic renal failure treated with growth-hormone-releasing hormone (GHRH)” in the journal Medicina. The subjects involved in this study were 9 children aged between 1 to 14 years old. They all suffered from chronic renal failure (CRF). The aim of this study was to investigate whether subcutaneous Sermorelin causes growth increase in children ailing from CRF. The subjects were categorized into 3 groups, the first group comprised of 3 children on conservative management, the second group comprised of 3 children on dialysis and the last group comprised 3 children who had undergone renal transplantation. Each of the three groups was administered with subcutaneous Sermorelin acetate (Geref ®) for a period of 3-6 months.
The results showed that the mean serum creatinine and urea levels remained stable in all the subjects except for two children on conservative management who showed an increase in their serum creatinine levels. The results also revealed that the rate of height increase in 5 of the subjects (3 on conservative management, one on dialysis and the other had undergone transplantation) averaged about 4.2cm/year (p < 0.05). Also, Geref® caused a higher peak in GH response among growth non-responders as compared to the growth responders (p < 0.05). The results obtained in this study do show that non-responders suffered from GH-resistance as demonstrated by the fact that they had high levels of GH but their growth was still stunted.
In summary, the findings of this study show that sermorelin does increase the rate of growth in GH-responsive CRF children, though it has no appreciable effect on the course of the CRF.
In conclusion, the above two studies show that Sermorelin can be used in research to diagnose cases of GH deficiency, stimulates GH secretion from the adenohypophysis, manage GH insufficiency and increase the rate of growth in GH-responsive CRF children.
The Sermorelin Acetate Peptide and H-GH
Sermorelin Acetate, which shares similar structure to CJC-1295, is a bio-identical synthetic hormone that is extremely effective in increasing the amount of H-GH. Human Growth Hormone is a hormone released by the body that controls the reproduction and growth of the cells and each of the organs in the body. At a young age, the body’s H-GH production is most active while the growth rate is at its highest point. After the age of 30, for every decade of life, there is a 14% reduction in H-GH production . By the age of 40, H-GH production is about 40 percent of what it was at the age of 20. With the further development of Growth Hormone Releasing Factors (GHRF), such as Modified GRF 1-29, H-GH production may possibly begin again by stimulating the pituitary gland.
Sermorelin Acetate and Related Research
Since 1980, scientists have been studying GHRH for many years. Dr. D. Rudman was testing Sermorelin as a tool for anti-aging processes and Dr. William Wehrenberg was looking at different peptides and particularly GHRH to identify which part of it is needed for pituitary gland stimulating response. His results after eliminating single amino acids showed that 29-acid-chains were held responsible for pituitary stimulation. Many research studies have concluded that Sermorelin is a well tolerated analogue of GHRH. As a result, this is suitable for use as a provocative test of growth hormone deficiency (Prakash and Goa 1999). In 1999, both researchers, Goa and Prakash checked Sermorelin Growth Hormone as provocative tasting method for deficiency of endogenous G-hormone. Sermorelin therapy increased the volume of hormone secreted by the stimulated pituitary gland, which is later converted by the liver into IGF-1. The increased amount of IGF-1 in the blood stream leads to many benefits from the use of Sermorelin: increasing metabolism and growth of new cells within the body’s organs and bones.
- On time delivery
- Free sample
- 24/7/360 after sales services for all of our products
- Exporting to South America (Brazil, …) , Australia, Middle East , Europe (Austria, Germany, Italy,…), USA, Asia (Vietnam, India, Thailand,…), Africa
- The highest peptide purity more than 98%
- HPLC and MS records for any orders
- Research and development our products in Austria through our experianced team
- More than 2 decades experiances
- Accept different currancies , Such as USD, EUR, AUD, CAD, JPY, TWD, AED , HKD, CNY (RMB), …
- OEM can be accepted
A peptide that I purchased recently has less powder in it than others I’ve gotten. Does this mean it doesn’t have the right MG?
Peptides due to their nature come in a variety of sizes and shapes. Normally after the lyophilization process has completed we have a peptide that is in a perfect cake. However there are times when it may break in transit or simply appear differently. This is no way effects the quality or potency of the product. It is simply an aesthetic issue. While we do try to always present a product that looks perfect, on occasion this isn’t possible. Proteins such as LR3 are very large in size and due to the requirement of a buffer will appear larger in size than a mod grf or ghrp. This is also normal.
If A Peptide Is 98% In Purity Then What Is The Remaining 2%?
The purity level indicated on a COA is simply a measurement of aminos that made it into the proper chain to form the peptide. The left over 2% are simply aminos that, for what ever reason, didn’t make it into the proper sequence.
What Are The Purity Levels Of The Peptides You Sell?
AP PEPTIDE will never sell a peptide that is less than 98% in purity from our catalog section. Many of our smaller peptide chains are well into the 99% purity range. We have manufacturing abilities that are quite often beyond the scope of smaller companies and therefore are able to achieve very high purity levels. Proteins such as IGF-1 LR3 are always receptor grade and always above 95% purity.
Two Vials Of The Same Peptide Have Different Amounts Of Powder. Does This Mean They Are Different In Milligrams?
Peptides, due to their nature, come in a variety of sizes and shapes. Normally after the lyophilization process has completed we have a peptide that is in a perfect cake. However there are times when it may break in transit or simply appear differently. This in no way effects the quality or potency of the product. It is simply an aesthetic issue. While we do try to always present a product that looks perfect, on occasion this isn’t possible.
Proteins are very large in size and due to the requirement of a buffer will appear larger in size than a mod grf or ghrp. This is also normal.
What Are Your Products Used For?
Peptides and Research serums are manufactured and sold to be used in a laboratory research setting. None of our products are intended for, nor are they manufactured for, diagnostic or therapeutic purposes in humans. Strong Peptide reserves the right to require additional verification of proper intent prior to fulfilling orders. Any orders that we feel aren’t for the specific intended purpose laid out in our Terms and Conditions will be denied. Truthfully, if you are asking this question then you shouldn’t be ordering from AP PEPTIDES.